NCI Drug Dictionary
The NCI Drug Dictionary contains technical definitions and synonyms for drugs/agents used to treat patients with cancer or conditions related to cancer. Each drug entry includes links to check for clinical trials listed in NCI's List of Cancer Clinical Trials.
- Bifidobacterium longum/Lactobacillus acidophilus/Enterococcus faecalis probiotic supplement
An orally bioavailable, probiotic supplement containing the microorganisms Bifidobacterium longum (B. longum), Lactobacillus acidophilus (L. acidophilus) and Enterococcus faecalis (E. faecalis), with potential immunomodulating, anti-diarrheal and mucosal protective activities. Upon oral ingestion, the naturally-occurring bacterial components in B. longum/L. acidophilus/E. faecalis probiotic supplement may improve digestion and help to maintain adequate colonization of the gastrointestinal (GI) tract by modulating the composition of the normal microflora. They produce lactic acid, hydrogen peroxide and other substances during fermentation, thereby creating an acidic environment that is unfavorable for pathogens. During colonization in the GI tract, the bacteria may also form a protective intestinal barrier, which may prevent damage to the mucosal epithelium, maintain the integrity of the epithelial barrier from potential damage by toxins and certain chemicals, and reduce the potential for attachment of pathogens. This further protects against bacterial translocation and infection. In addition, this agent may reduce the secretion of pro-inflammatory cytokines and may potentiate natural and acquired immunity. Altogether, this may increase immunity, prevent GI mucosal damage, malabsorption, inflammation, and reduce diarrhea.
Check for active clinical trials using this agent. (NCI Thesaurus)
Synonym: B. longum/L. acidophilus/E. faecalis probiotic supplement
Bifidobacterium longum/Lactobacillus acidophilus/Enterococcus faecalis supplement
Foreign brand name: Bifico